Investor relations

Establish and maintain the board as a well-functioning, balanced team led by the chair (QCA Principle 6)

The Board comprises a balance of Executive and Non-Executive Directors with relevant industry, commercial and financial experience. All Directors are expected to devote sufficient time to their roles and to contribute effectively to Board discussions. The Chairman provides leadership to the Board and ensures its effective operation, while maintaining a clear distinction between oversight and executive management responsibilities. To enable the Board to discharge its duties, all Directors have full and timely access to information. The Board is aware of the commitments and interests of its Directors and changes to these commitments and interests are reported to and, where appropriate, agreed with the rest of the Board.

 

Board and Committee Attendance 2025

 During 2025, there were considerable changes to the Board and Board Committee composition. In June 2025, Juliet Thompson and Brian Howlett stepped down from the Board. In September 2025 Andrew Newland and Ian Griffiths stepped down from the board and Jan Groen transitioned from Non-Executive Chairman to Executive Chairman.

Jan GroenBrian HowlettJoseiph EidJuliet ThompsonAndrew NewlandIan Griffiths
Board20/206/617/205/57/77/7
Committee of the Board*N/AN/AN/AN/AN/AN/A
Audit2/22/21/22/2N/AN/A
Remuneration1/1N/A1/1N/AN/AN/A
Nomination3/3N/A3/3N/AN/AN/A

Request a meeting with






    CelLBxHealth Logo
    Privacy overview

    This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.